Fibrosis - Pipeline Review, H1 2017

  • ID: 4189148
  • Drug Pipelines
  • 132 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • Anima Biotech Ltd
  • Encycle Therapeutics Inc
  • GlycoMimetics Inc
  • Insmed Inc
  • Lycera Corp
  • MORE
Fibrosis - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis - Pipeline Review, H1 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.

Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 30 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • Anima Biotech Ltd
  • Encycle Therapeutics Inc
  • GlycoMimetics Inc
  • Insmed Inc
  • Lycera Corp
  • MORE
Introduction

Fibrosis - Overview

Fibrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Fibrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibrosis - Companies Involved in Therapeutics Development

Acceleron Pharma Inc

Aelis Farma SAS

Allakos Inc

Anima Biotech Ltd

Bristol-Myers Squibb Company

Calypso Biotech SA

Complexa Inc

Encycle Therapeutics Inc

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Genfit SA

GlycoMimetics Inc

Hanmi Pharmaceuticals Co Ltd

iBio Inc

Immunomet Therapeutics Inc

Inception Sciences Inc

Insmed Inc

Inventiva

Ironwood Pharmaceuticals Inc

Isarna Therapeutics GmbH

Lycera Corp

Neumedicines Inc

Novartis AG

Palatin Technologies Inc

Ribomic Inc

Scholar Rock Inc

SciFluor Life Sciences LLC

SK Chemicals Co Ltd

UCB SA

VivaCell Biotechnology Espana SL

Fibrosis - Drug Profiles

ACE-2798 - Drug Profile

AEF-0118 - Drug Profile

AK-002 - Drug Profile

Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile

CALY-001 - Drug Profile

CWHM-12 - Drug Profile

elafibranor - Drug Profile

G-XXX - Drug Profile

IB-DMD - Drug Profile

IBIOCFB-03 - Drug Profile

IM-156 - Drug Profile

INS-1007 - Drug Profile

ISTH-1106 - Drug Profile

IW-1701 - Drug Profile

IW-1973 - Drug Profile

LYC-53976 - Drug Profile

Monoclonal Antibodies for Fibrosis - Drug Profile

Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile

Monoclonal Antibody 2 for Fibrosis - Drug Profile

Monoclonal Antibody for Fibrotic Scar - Drug Profile

Monoclonal Antibody to Activate BMP7 for Fibrosis - Drug Profile

NCE-401 - Drug Profile

Neumomir - Drug Profile

NMIL-121 - Drug Profile

OCX-063 - Drug Profile

PAT-048 - Drug Profile

PL-5028 - Drug Profile

PRI-724 - Drug Profile

Proteins for Central Nervous System Disorders and Fibrosis - Drug Profile

RBM-003 - Drug Profile

RBM-007 - Drug Profile

Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile

RG-6125 - Drug Profile

Small Molecule for Fibrosis - Drug Profile

Small Molecule for Fibrosis - Drug Profile

Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile

Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile

Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis - Drug Profile

Small Molecules for Fibrosis and Inflammatory Diseases - Drug Profile

Small Molecules for Fibrosis and Oncology - Drug Profile

Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile

Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile

Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile

Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology - Drug Profile

Small Molecules to Inhibit SphK1 for Autoimmune Disorders, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile

SRI-31277 - Drug Profile

ST-2001 - Drug Profile

Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology - Drug Profile

VCE-0048 - Drug Profile

X-165 - Drug Profile

XOMA-089 - Drug Profile

Fibrosis - Dormant Projects

Fibrosis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Fibrosis, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Fibrosis - Pipeline by Acceleron Pharma Inc, H1

Fibrosis - Pipeline by Aelis Farma SAS, H1

Fibrosis - Pipeline by Allakos Inc, H1

Fibrosis - Pipeline by Anima Biotech Ltd, H1

Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1

Fibrosis - Pipeline by Calypso Biotech SA, H1

Fibrosis - Pipeline by Complexa Inc, H1

Fibrosis - Pipeline by Encycle Therapeutics Inc, H1

Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H1

Fibrosis - Pipeline by Five Prime Therapeutics Inc, H1

Fibrosis - Pipeline by Genfit SA, H1

Fibrosis - Pipeline by GlycoMimetics Inc, H1

Fibrosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1

Fibrosis - Pipeline by iBio Inc, H1

Fibrosis - Pipeline by Immunomet Therapeutics Inc, H1

Fibrosis - Pipeline by Inception Sciences Inc, H1

Fibrosis - Pipeline by Insmed Inc, H1

Fibrosis - Pipeline by Inventiva, H1

Fibrosis - Pipeline by Ironwood Pharmaceuticals Inc, H1

Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1

Fibrosis - Pipeline by Lycera Corp, H1

Fibrosis - Pipeline by Neumedicines Inc, H1

Fibrosis - Pipeline by Novartis AG, H1

Fibrosis - Pipeline by Palatin Technologies Inc, H1

Fibrosis - Pipeline by Ribomic Inc, H1

Fibrosis - Pipeline by Scholar Rock Inc, H1

Fibrosis - Pipeline by SciFluor Life Sciences LLC, H1

Fibrosis - Pipeline by SK Chemicals Co Ltd, H1

Fibrosis - Pipeline by UCB SA, H1

Fibrosis - Pipeline by VivaCell Biotechnology Espana SL, H1

Fibrosis - Dormant Projects, H1

Fibrosis - Dormant Projects, H1 2017 (Contd..1), H1

List of Figures:

Number of Products under Development for Fibrosis, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acceleron Pharma Inc
  • Aelis Farma SAS
  • Allakos Inc
  • Anima Biotech Ltd
  • Bristol-Myers Squibb Company
  • Calypso Biotech SA
  • Complexa Inc
  • Encycle Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Five Prime Therapeutics Inc
  • Genfit SA
  • GlycoMimetics Inc
  • Hanmi Pharmaceuticals Co Ltd
  • iBio Inc
  • Immunomet Therapeutics Inc
  • Inception Sciences Inc
  • Insmed Inc
  • Inventiva
  • Ironwood Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • Lycera Corp
  • Neumedicines Inc
  • Novartis AG
  • Palatin Technologies Inc
  • Ribomic Inc
  • Scholar Rock Inc
  • SciFluor Life Sciences LLC
  • SK Chemicals Co Ltd
  • UCB SA
  • VivaCell Biotechnology Espana SL
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll